Stay updated on Durvalumab vs Placebo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab vs Placebo in Early NSCLC Clinical Trial page.

Latest updates to the Durvalumab vs Placebo in Early NSCLC Clinical Trial page
- ChecktodayChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This suggests a shift towards a more generalized presentation of study locations.SummaryDifference49%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
- Check22 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.3%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
- Check36 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and includes a new section on HHS Vulnerability Disclosure.SummaryDifference0.8%
- Check43 days agoChange DetectedThe web page has updated its version from v2.16.5 to v2.16.6 and changed the date from April 9, 2025, to July 14, 2025.SummaryDifference0.9%
Stay in the know with updates to Durvalumab vs Placebo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab vs Placebo in Early NSCLC Clinical Trial page.